Hair Therapy for Hair Loss: Every Option Ranked by Evidence (2026)

Introduction: Why “Hair Therapy” Needs a Unified Map, Not Another Silo

Hair loss is common, but the conditions behind it differ. Androgenetic alopecia (AGA) affects an estimated 50 million men and 30 million women in the United States. Alopecia areata affects roughly 6.8 million Americans and 147 million people worldwide. These two conditions work through different biological mechanisms, yet they are often grouped together in online searches.

Most available content covers only part of the picture. Some articles focus on new AGA drugs, others explain JAK inhibitors for alopecia areata, and others report only surgical statistics. Readers are left to assemble their own decision framework.

This guide organizes these options into one evidence-graded system for 2026. It covers pharmacologic, device-based, regenerative, biologic, cosmetic-camouflage, and surgical therapies, and matches each one to a candidate profile. Where the research conflicts, as it does for platelet-rich plasma (PRP), both sides are presented.

The decision also affects quality of life. Among women with hair loss, 78% report shame, anxiety, or depression. Choosing a therapy is a health decision, not a casual cosmetic one.

The Two Root Causes Every Therapy Map Must Account For

Treatment should be chosen based on diagnosis, not popularity. Pattern hair loss and autoimmune hair loss have different causes, and each requires a different class of treatment.

Androgenetic Alopecia (AGA): The Hormonal/Genetic Pathway

AGA is the most common form of hair loss, affecting 85% of men and 40% of women. It occurs when genetically predisposed follicles are sensitive to dihydrotestosterone (DHT), a hormone that gradually shrinks them.

The condition is progressive and often starts early:

Roughly 95% of male hair loss is attributable to AGA.
Among white men, 16% of those aged 18 to 29 show at least moderate AGA (Norwood III or above).
That figure rises to 53% among men aged 40 to 49.

In a 390-patient university hospital study, 38.5% of men and 41% of women had severe AGA. These numbers support early intervention.

Alopecia Areata and Autoimmune Hair Loss: The Immune Pathway

In alopecia areata, the immune system attacks hair follicles, causing patchy or diffuse loss that looks different from the gradual thinning of pattern baldness. Approximately 6.8 million people in the U.S. and 147 million worldwide are affected at any given time.

This distinction matters clinically. AGA therapies such as finasteride and minoxidil do not treat autoimmune hair loss, and autoimmune therapies do not treat AGA. Generic “hair loss treatment” content often overlooks this mismatch.

Other Contributing Patterns Worth Ruling Out

The Journal of the American Academy of Dermatology’s clinical approach to hair loss lists other causes to consider:

Telogen effluvium: temporary, widespread shedding, often triggered by stress or illness.
Medication-induced shedding: hair loss caused by certain drugs.

A newer signal emerged in 2026: a systematic review linked GLP-1 receptor agonists (such as Ozempic and Wegovy) to non-scarring hair loss, and public interest in this link has risen steadily since 2023. Readers taking these medications should mention them during evaluation.

A professional diagnosis should come before any treatment below. A misdiagnosis can mean months spent on the wrong treatment class.

How This Article Grades Evidence: A Transparent Methodology

Each therapy in this guide is placed in one of the following categories:

Tier 1: Strong, replicated evidence from randomized controlled trials (RCTs) and meta-analyses.
Tier 2: Moderate or mixed evidence, usually best used as an add-on (adjunct) to other treatment.
Tier 3: Emerging or investigational therapies that are promising but not yet proven at scale.
Cosmetic Camouflage and Surgical: Graded on procedural and patient-reported outcomes rather than drug-trial standards.

One regulatory distinction is often blurred. FDA approval applies to drugs and requires rigorous clinical trials. FDA 510(k) clearance applies to devices and only shows that a device is substantially equivalent to an existing one. The HairMax LaserComb became the first cleared low-level laser device in 2007 through the 510(k) pathway.

Where studies disagree, this guide shows the disagreement instead of choosing the more flattering result. Each tier also includes an ideal candidate profile so readers can see where they fit.

Tier 1: First-Line Pharmacologic Therapy for AGA

This tier has the strongest and longest-standing clinical trial evidence for pattern hair loss.

Finasteride: The DHT-Blocking Standard

Finasteride is an oral 5-alpha reductase inhibitor, a drug that blocks the enzyme that produces DHT. It has been FDA-approved since 1997 and reduces DHT by approximately 70%. Across studies, it:

stabilizes hair loss in roughly 65-83% of men,
promotes regrowth in about 66%, and
shows 85%+ stabilization or improvement at five years.

Candidate profile: Men with early-to-moderate AGA who want to stop progression. It is not indicated for women of childbearing potential or for autoimmune hair loss.

Dutasteride: The Emerging Oral Leader

A 2025 network meta-analysis compared oral treatments taken alone. Oral dutasteride 0.5 mg/day ranked highest for improving total hair density at 24 weeks, with a SUCRA score of 96.3% (a statistical measure of how likely a treatment is to rank first). Dutasteride blocks both Type I and Type II 5-alpha reductase, while finasteride blocks mainly Type II. This broader action explains its stronger ranking.

Candidate profile: Patients who have plateaued on finasteride or want the top-ranked oral option. It should be used under physician supervision because it is prescribed off-label for hair loss in many regions.

Topical Minoxidil: The Over-the-Counter Foundation

Minoxidil is the American Academy of Dermatology’s baseline recommendation. The AAD notes that it helps early hair loss but cannot regrow a full head of hair, and that it works better alongside another treatment.

The combination data supports this. Minoxidil 5% plus finasteride 1 mg achieved 94.1% improvement, compared with 80.5% for finasteride alone and 59.0% for minoxidil alone. The difference was statistically significant.

Candidate profile: Anyone with early-stage AGA. It can be used alone but works best combined with finasteride or dutasteride.

Tier 1 (Autoimmune Track): JAK Inhibitors for Severe Alopecia Areata

JAK inhibitors are the first-line drug class for autoimmune hair loss. They are not interchangeable with AGA drugs. Since 2022, the FDA has approved three for severe alopecia areata. Results are measured with the SALT score, which estimates the percentage of scalp without hair; a score of 20 or lower means at least 80% scalp coverage.

Drug	Patients Reaching SALT ≤20
Olumiant (baricitinib)	35-40% at 36 weeks
Litfulo (ritlecitinib)	23% at week 24
Leqselvi (deuruxolitinib)	31% at 24 weeks

Candidate profile: Patients with severe alopecia areata and significant scalp involvement, managed by a dermatologist or specialist. This group is separate from the pattern-loss population most hair restoration practices treat.

Tier 2: Device-Based and Mechanical Therapies

The evidence in this tier is moderate. These therapies work best as adjuncts rather than standalone solutions.

Low-Level Light Therapy (LLLT)

LLLT devices use low-power light to stimulate follicles. They are cleared through the FDA’s 510(k) pathway, not approved through drug trials.

In one real-world dataset, an FDA-cleared laser helmet used by 1,383 AGA patients achieved nearly 80% overall clinical effectiveness. However, peer-reviewed meta-analyses of double-blinded RCTs consistently show smaller effects than minoxidil or finasteride.

Candidate profile: Patients who want a low-risk, at-home adjunct to medication, or who cannot tolerate topical or oral drugs.

Microneedling: Strong as an Adjunct, Weak Alone

Microneedling creates tiny punctures in the scalp to trigger a healing response and improve absorption of topical treatments.

Combined with other treatment: A 2024 meta-analysis of 13 RCTs (696 patients) found that microneedling combined with other therapy significantly outperformed any single treatment for hair density.
Used alone: A trial of 30 men receiving four monthly sessions of microneedling alone found no improvement in hair density.

Candidate profile: Patients already using minoxidil or finasteride who want to boost their results. It does not replace medication.

Tier 2: Regenerative and Biologic Injectables (Where the Evidence Genuinely Conflicts)

This section presents both sides of the data, because clinic marketing in this category often shows only favorable results.

Platelet-Rich Plasma (PRP) Therapy

PRP uses a concentrate of the patient’s own blood platelets, which contain growth factors, injected into the scalp.

Favorable evidence: An older meta-analysis of 10 RCTs (318 participants) found PRP significantly increased hair density, by a mean of 25.09 hairs/cm² (p = 0.002). The effect was stronger in men.

Counter-evidence: A larger, more rigorous 2025 systematic review in Dermatology and Therapy analyzed 43 RCTs (1,877 participants). When 13 comparable studies were pooled, it found no significant overall effect on hair thickness (p = 0.18).

Why the results differ: PRP preparation methods, injection protocols, and outcome measures vary widely between trials, which makes studies hard to compare.

PRP’s evidence is more consistent when it is paired with surgery. Three controlled studies (217 participants) found that adding PRP to hair transplantation improved hair density and follicle survival and led to earlier growth.

Candidate profile: Best used as a complement to surgical restoration rather than as a primary standalone therapy, until trial data becomes more consistent.

Stem Cell / Exosome Therapy

The scientific rationale for this therapy is promising, since it is based on growth factor signaling. However, as of 2026 it is less standardized than PRP and has limited large-scale RCT support. Academic reviews identify cell-based therapies as a priority for future research because they may directly restore the follicle’s ability to regenerate.

Candidate profile: Patients interested in cutting-edge regenerative approaches who understand that the evidence is less mature than for PRP and who discuss it candidly with a provider.

Device-Delivered Topicals: Ultrasound-Assisted Serum Delivery

Needle-free ultrasound devices, such as Alma TED, are designed to deliver hair growth serums deeper into the scalp without injections. The typical protocol is:

three sessions about one month apart,
maintenance every 6-12 months, and
visible results within one month, according to manufacturers.

The evidence is still emerging compared with PRP and Tier 1 drugs. It is best viewed as a technology that improves delivery of other treatments, not as a proven independent therapy with large-scale peer-reviewed support.

Candidate profile: Patients who want to avoid needles and are looking for a non-invasive adjunct to an established Tier 1 regimen.

Tier 3: Emerging and Pipeline Therapies to Watch

These therapies are investigational. Their early data is promising, but they are not standard of care or widely available in 2026.

Clascoterone: A Potential New Mechanism After 30 Years

Clascoterone is a topical androgen receptor inhibitor. Instead of lowering DHT like finasteride and dutasteride, it blocks DHT from acting on the follicle. Phase 3 results released in December 2025 showed up to 539% relative improvement in hair count compared with placebo. If confirmed, it would be the first new mechanism of action for AGA in over 30 years.

PP405 and Follicle-Reactivation Science

PP405 targets dormant hair follicle stem cells to restart growth, rather than only slowing loss. In Phase II trials, 31% of men achieved more than a 20% increase in hair density. It is still early-stage but works differently from every current Tier 1 and Tier 2 option.

Antibody Therapies and the Next Research Frontier

Academic reviews recommend that future drug development focus on two areas:

Antibody therapies, which can precisely target key molecular pathways.
Cell-based therapies, which may directly restore follicle regeneration.

Readers should be skeptical of commercial claims that “hair cloning” will soon be available. That claim is speculative and poorly sourced compared with the more cautious academic view.

Candidate profile: None yet. This category is a watch list, not an actionable 2026 option.

Cosmetic Camouflage Tier: Scalp Micropigmentation (SMP)

SMP does not regrow hair. It is a cosmetic technique that creates the appearance of density, and it has strong patient-reported satisfaction.

Outcomes: Immediately after treatment, visual density scores averaged 8.7 ± 1.1 overall. AGA cases averaged 9.1 ± 0.5, and 85.7% of AGA patients reported being “very satisfied.”

The process: SMP is a medical tattooing technique that uses up to 14,000 micro-insertions per session to mimic hair follicles.

Standard treatment requires at least 3-4 sessions spaced 2-6 weeks apart.
Scar camouflage usually requires 4 sessions spaced 4-6 weeks apart.

Applications:

Creating the look of density for shaved or buzzed styles.
Concealing scars from prior transplants or injuries, with reported improvement in scar appearance of 75-85%.

Candidate profile: Patients who want an immediate, non-invasive visual result, those concealing transplant scars, or those combining SMP with surgery for a fuller final look.

The Definitive Tier: Surgical Hair Restoration

Surgery is the only option that permanently moves a patient’s own living follicles to thinning areas. It is evaluated on procedural outcomes rather than drug-trial statistics.

Follicular Unit Extraction (FUE): The Global Standard

According to ISHRS data, FUE accounts for over 75% of surgical hair transplants worldwide, making it the current global standard. Surgeons remove individual follicles and transplant them, which offers:

a minimally invasive procedure,
no linear scar, and
minimal downtime.

Women are the fastest-growing group of patients: female surgical hair restoration patients increased 16.5% between 2021 and 2024.

Candidate profile: Patients with stabilized AGA, often already on Tier 1 medication, who want permanent density. This includes beard and eyebrow restoration candidates.

Follicular Unit Transplantation (FUT): Strip Method for High-Yield Cases

FUT removes a strip of scalp from the donor area, allowing a high number of grafts in a single session. Advanced trichophytic closure, a technique that lets hair grow through the incision line, minimizes scar visibility.

Candidate profile: Patients with large areas to restore who prioritize graft yield per session over FUE’s no-linear-scar advantage.

Why Surgery Is Often the Endpoint, Not the Starting Point

The tiers above usually work alongside surgery rather than competing with it:

Medication stabilizes existing native and donor hair.
Devices and injectables may improve graft survival.
Surgery permanently redistributes follicles.

In many cases, the earlier tiers are clinical prerequisites for surgery. Content that covers only one category tends to miss this sequence.

Combining Modalities: Building a Personal Multi-Tier Protocol

Most patients use a sequence of therapies rather than a single one. A typical protocol might include:

finasteride plus minoxidil for stabilization,
PRP as a transplant adjunct, and
SMP for camouflage while transplanted hair grows in.

PRP combined with FUE has been shown to increase blood supply to follicles and raise graft growth rates. Combination medication also outperforms either drug alone (94.1% improvement versus 80.5% and 59.0%). Combining validated tiers is often more effective than searching for a single solution.

However, therapies should not be added just because they are marketed as add-ons. Each one should be chosen based on its own evidence tier and how well it fits the patient.

Find Your Tier: A Candidate Self-Assessment Framework

Situation	Evidence-Matched Path
Early-stage AGA, minimal thinning	Tier 1 minoxidil/finasteride, plus optional Tier 2 device adjuncts
Moderate-to-advanced AGA, plateaued on medication	Consider dutasteride and PRP as an adjunct; begin a surgical consultation
Severe, patchy, or diffuse autoimmune loss	JAK inhibitor evaluation with a dermatologist or specialist, not AGA therapies
Stable donor area, seeking permanent density	FUE or FUT candidacy, potentially combined with PRP
Shaved-head look or scar concealment	SMP as the primary solution
Interest in cutting-edge options	Tier 3 pipeline therapies: monitor, don’t rely on yet

Readers who are unsure where they fit should get a professional diagnostic consultation before starting any therapy.

Conclusion: From Overwhelm to a Clear Next Step

The evidence sorts hair loss therapies into clear categories:

Tier 1: Medications for AGA and JAK inhibitors for alopecia areata.
Tier 2: Devices and regenerative injectables, with moderate or mixed evidence.
Tier 3: Pipeline therapies to watch.
Cosmetic camouflage: SMP, for appearance without regrowth.
Surgery: The only permanent structural solution.

With evidence grades and candidate profiles in one place, readers can identify their likely next step. In most cases, the right therapy is not a single treatment but a sequenced combination based on diagnosis, severity, and goals.

Ready to Find Your Evidence-Matched Path? Talk to a Specialist

Hair Transplant Specialists offers personalized evaluation with a board-certified team. The team includes Dr. Sharon Keene, former President of the International Society of Hair Restoration Surgery, and Dr. Roy Stoller, who has more than 20 years of experience and serves as a board certification examiner.

The practice covers every tier in this guide under one roof:

Non-surgical: finasteride, minoxidil, LLLT, Alma TED, PRP, and stem cell/exosome therapy.
Surgical and cosmetic: FUE, FUT, facial hair transplants, and scalp micropigmentation.

Each consultation starts with a diagnostic evaluation to determine the type and severity of hair loss before any treatment is recommended. Financing options and treatment planning are discussed directly during the visit.

To schedule a consultation and receive a personalized, evidence-based treatment plan, contact Hair Transplant Specialists at (651) 393-5399 or visit INeedMoreHair.com.